Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.